Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome for mRNA-1273 vaccine usage in Japan by December 31, 2024?
Continued use without changes • 25%
Usage restrictions for certain age groups • 25%
Temporary suspension • 25%
Permanent ban • 25%
Official announcements from Japanese health authorities or government websites
Japanese Scientists Link Covid mRNA-1273 Shots to Surge in Deadly Heart Failure in Youngsters
Jul 20, 2024, 04:09 PM
A group of Japanese scientists has used a specialized biopsy technique to prove that Covid mRNA shots are causing cases of deadly heart failure to surge globally. Dr. Hiroyuki Yamamoto from the Department of Cardiovascular Medicine at Narita-Tomisato Tokushukai Hospital led the research. The discovery was made using an endomyocardial biopsy (EMB) instead of the standard technique, which would easily miss this evidence. The findings have raised concerns about cardiac dysfunction in youngsters following the introduction of mRNA injections, including the mRNA-1273 third-dose. The study highlights the potential risks associated with Covid-19 vaccines, including inflammatory dilated cardiomyopathy, fatal myocarditis, and increased emergency cardiovascular events among the under-40 population in Israel during the vaccine rollout.
View original story
Less than 10 million • 25%
10-20 million • 25%
21-30 million • 25%
More than 30 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No change in safety guidelines • 25%
Minor safety warning issued • 25%
Major safety warning issued • 25%
Vaccine approval revoked • 25%
Yes • 50%
No • 50%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Less than 50% • 25%
50-70% • 25%
71-90% • 25%
More than 90% • 25%
0 • 25%
5 or more • 25%
3-4 • 25%
1-2 • 25%